MARKET NEWS

Immutep Enters Into Clinical Trial Collaboration, Service, and Supply Agreement
Sublimity Therapeutics Receives IND Clearance
BioTime Enters Into Exclusive Agreement With Orbit Biomedical
Lilly Announces Agreement to Acquire Loxo Oncology
Athenex Announces Completion of Target Enrollment in Phase III Study
Vital Therapies & Immunic Therapeutics Announce Transaction to Create Leading Company

  FEATURED EDITORIAL

  COMPANY PROFILE

Pharmaceutical formulators continue to strive to create market leading products with maximum efficacy, quality, and performance. However, the inability to achieve API solubility and stability are common day-to-day challenges for formulators. With the help from Croda’s superior quality and ultrahigh purity specialty line of excipients, formulators are able to surpass these barriers, making Croda the supplier of choice in the global pharmaceutical market. With products being manufactured at multiple sites throughout the world, we are able to provide local and consistent supply of one of the widest ranges of chemical specialties, surfactants, and high-purity lipids available to the pharmaceutical industry. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Lonza & Takeda Partner in Development & Manufacture of Cancer Treatment

Lonza & Takeda Partner in Development & Manufacture of Cancer Treatment

Lonza recently announced another major milestone in its multiproduct partnership with Takeda.

MedPharm Announces Expansion of US Center of Excellence

MedPharm Announces Expansion of US Center of Excellence

MedPharm Ltd recently announced the expansion of its US Center of Excellence in Durham, NC, in response to increasing service demand for its topical and transdermal formulation development and performance testing services.

PCI Pharma Services Announces -Million Expansion of Biotech Technologies, Including Advanced Injectable Delivery Forms

PCI Pharma Services Announces $20-Million Expansion of Biotech Technologies, Including Advanced Injectable Delivery Forms

Leading global biopharmaceutical services provider PCI Pharma Services (PCI) has announced a momentous investment in support of biologic medicines and advanced injectable delivery forms, totaling more than $20 million. 

Catalent Makes Significant Investment to Expand Biologics Capacity & Capabilities

Catalent Makes Significant Investment to Expand Biologics Capacity & Capabilities

Catalent, Inc. recently announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.

Bristol-Myers Squibb’s Acquisition of Celgene Could Position Company Amongst Top Five Most Profitable Pharma Giants

Bristol-Myers Squibb’s Acquisition of Celgene Could Position Company Amongst Top Five Most Profitable Pharma Giants

Following Bristol-Myers Squibb’s (BMS) announcement that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on this significant merger.

“Amidst the inevitable transformation of the pharmaceutical industry, top drug companies are determined to stay in the spotlight and emerge as highly profitable global pharma giants. BMS and Celgene are already among the 10 largest drug makers in the US;

 » Read more about: Bristol-Myers Squibb’s Acquisition of Celgene Could Position Company Amongst Top Five Most Profitable Pharma Giants  »

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 23 – Drug Delivery
January 30 – Bioavailability